An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)

2023-508444-22-01 Protocol SAMBA-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 26 Aug 2024 · Status Ongoing, recruiting · 2 EU/EEA countries · 7 sites · Protocol SAMBA-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 48
Countries 2
Sites 7

Chronic hepatitis B infection

Key facts

Sponsor
Region Midtjylland
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
26 Aug 2024 → ongoing
Decision date (initial)
2024-06-28
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic hepatitis B infection

VersionLevelCodeTermSystem organ class
20.1 PT 10008910 Chronic hepatitis B 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Region Midtjylland

Sponsor organisation
Region Midtjylland
Address
Palle Juul-Jensens Boulevard 99
City
Aarhus N
Postcode
8200
Country
Denmark

Scientific contact point

Organisation
Region Midtjylland
Contact name
Department of Infectious Diseases

Public contact point

Organisation
Region Midtjylland
Contact name
Department of Infectious Diseases

Locations

2 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ongoing, recruiting 24 6
Germany Ongoing, recruiting 24 1
Rest of world 0

Investigational sites

Denmark

6 sites · Ongoing, recruiting
Kolding Sygehus
Dept. of Infectious Diseases, Sygehusvej 24, 6000, Kolding
Odense University Hospital
Dept. of Infectious Diseases, Kloevervaenget 47, 5000, Odense C
Hvidovre Hospital
Dept. of Infectious Diseases, Kettegaard Alle 36, 2650, Hvidovre
Rigshospitalet
Dept. of Infectious Diseases, Blegdamsvej 9, 2100 Cph, København
Aalborg University Hospital
Dept. of Infectious Diseases, Moelleparkvej 4, 9000, Aalborg
Region Midtjylland
Dept. of Infectious Diseases, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N

Germany

1 site · Ongoing, recruiting
Charite Universitaetsmedizin Berlin KöR
Department of Infectious Diseases and Critical Care Medicine, Augustenburger Platz 1, Wedding, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2024-08-26 2024-08-26
Germany 2024-09-16 2024-09-16

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-18 Denmark Acceptable
2024-06-28
2024-06-28
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-07-01 Denmark Acceptable
2024-06-28
2024-07-01
3 NON SUBSTANTIAL MODIFICATION NSM-3 2024-09-05 Denmark Acceptable
2024-06-28
2024-09-05
4 NON SUBSTANTIAL MODIFICATION NSM-4 2024-09-16 Acceptable
2024-06-28
2024-09-16
5 SUBSTANTIAL MODIFICATION SM-1 2025-01-21 Denmark Acceptable
2025-03-21
2025-03-26
6 SUBSTANTIAL MODIFICATION SM-5 2025-07-02 Denmark Acceptable
2025-08-31
2025-09-01